Implantable Sensor Enters First Clinical Trial

Senseonics Holdings announces that the extended life Eversense XL sensor that lasts up to 180 days has been implanted in the first US study participant as part of the clinical trial for pre-market application submission to the Food and Drug Administration. The study is intended to evaluate the safety and efficacy of the Eversense CGM system in people with diabetes over a 180-day period.

 

Approximately 180 study participants at up to 15 locations across the United States are planned to enroll in the study. The Eversense XL sensor previously received the CE Mark and is currently marketed to patients across the European Union.

Sponsored by Digi-Key

Analog Devices ADIS16500/05/07 Precision Miniature MEMS IMU Available Now from Digi-Key

The Analog Devices’ ADI ADIS16500/05/07 precision miniature MEMS IMU includes a triaxial gyroscope and a triaxial accelerometer. Each inertial sensor in the MEMS IMU combines with signal conditioning that optimizes dynamic performance.

 

Senseonics also announced that the company has completed its submission of PMA supplements to the FDA to secure an insulin dosing claim and to remove the contraindication related to the Magnetic Resonance Imaging (MRI) exposure on the 90-day system which is currently available in the United States.

 

For more information, visit Senseonics.

Read more on

Suggested Articles

Research shows biggest growth expected in Latin America and Asia, as holographic telepresence emerges

Semiconductor Industry Association makes pitch for tax incentives and grants to chipmakers to compete with other countries as backed by lawmakers

The Semiconductor Industry Association sees significant uncertainty for chip sales in coming months, although May numbers were up by 6% globally.